Novartis has been focusing on rare diseases for the last 10 or more years. I'm sure other pharmaceutical companies are doing the same. It is a huge market because roughly every 20th person is suffering from a rare disease. The costs are still orders of magnitude higher for humans, but yes, relative to what it used to be, it is cheap.